B. Katzung, S. Masters, and T. A. , Basic and clinical pharmacology, 2012.

J. Reiffel, Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice, The American Journal of Cardiology, vol.85, issue.10, pp.46-52, 2000.
DOI : 10.1016/S0002-9149(00)00906-1

J. Reiffel, Issues in the use of generic antiarrhythmic drugs, Current Opinion in Cardiology, vol.16, issue.1, pp.23-29, 2001.
DOI : 10.1097/00001573-200101000-00004

G. Buehler, History of bioequivalence for critical dose drugs, 2010.

J. Peters, D. Hixon, and D. Conner, Generic drugs - safe, effective, and affordable, Dermatologic Therapy, vol.31, issue.3A, pp.229-240, 2009.
DOI : 10.1111/j.1529-8019.2009.01236.x

B. Davit, P. Nwakama, and G. Buehler, Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration, Annals of Pharmacotherapy, vol.84, issue.9, pp.1583-1597, 2009.
DOI : 10.1345/aph.1M141

D. Schuirmann, A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability, Journal of Pharmacokinetics and Biopharmaceutics, vol.12, issue.6, pp.657-680, 1987.
DOI : 10.1007/BF01068419

C. For, M. Products-for-human, and . Use, Guideline on the investigation of bioequivalence 12) Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs, Hottinger M Am J Law Med, vol.38, pp.667-689, 2010.

P. Meredith, Bioequivalence and other unresolved issues in generic drug substitution, Clinical Therapeutics, vol.25, issue.11, pp.2875-2890, 2003.
DOI : 10.1016/S0149-2918(03)80340-5

G. Wilkinson, Drug Metabolism and Variability among Patients in Drug Response, New England Journal of Medicine, vol.352, issue.21, pp.2211-2221, 2005.
DOI : 10.1056/NEJMra032424

R. Verbeeck and F. Musuamba, The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action, Journal of Pharmacy & Pharmaceutical Sciences, vol.15, issue.3, pp.376-388, 2012.
DOI : 10.18433/J3VC8J

B. Rocca and C. Patrono, Determinants of the interindividual variability in response to antiplatelet drugs, Journal of Thrombosis and Haemostasis, vol.69, issue.8, pp.1597-1602, 2005.
DOI : 10.1161/01.CIR.0000130846.46168.03

L. Yu, Approaches to demonstrate bioequivalence of narrow therapeutic index drugs, 2011.

L. Yu, Quality and bioequivalence standards for narrow therapeutic index drugs 21. US Food and Drug Administration (2010) Draft guidance on flecainide acetate 22. US Food and Drug Administration (2012) Center for Drug Evaluation and Research (CDER) Draft guidance on warfarin sodium, 2011.

X. Zhang, N. Zheng, R. Lionberger, and L. Yu, Innovative approaches for demonstration of bioequivalence: the US FDA perspective, Therapeutic Delivery, vol.4, issue.6, pp.725-740, 2013.
DOI : 10.4155/tde.13.41

L. Endrenyi and L. Tothfalusi, Determination of Bioequivalence for Drugs with Narrow Therapeutic Index: Reduction of the Regulatory Burden, Journal of Pharmacy & Pharmaceutical Sciences, vol.16, issue.5, pp.676-682, 2013.
DOI : 10.18433/J31K51

A. Camm, G. Lip, D. Caterina, and R. , 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation, Revista Espa??ola de Cardiolog??a (English Edition), vol.66, issue.1, pp.2719-2747, 2012.
DOI : 10.1016/j.rec.2012.11.003

V. Fuster, L. Rydén, and D. Cannom, ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.48, issue.4, p.177292, 2006.
DOI : 10.1016/j.jacc.2006.07.018

J. Anderson, J. Halperin, and N. Albert, Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations): A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, vol.127, issue.18, pp.1935-1944, 2013.
DOI : 10.1161/CIR.0b013e318290826d

D. Holmes, J. Becker, and C. Granger, ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution, Journal of the American College of Cardiology, vol.58, issue.12, pp.1290-1310, 2011.
DOI : 10.1016/j.jacc.2011.06.001

D. Roden and R. Woosley, Flecainide, New England Journal of Medicine, vol.315, issue.1, pp.36-41, 1986.
DOI : 10.1056/NEJM198607033150106

R. Woosley, L. Siddoway, H. Duff, and D. Roden, Flecainide dose-response relations in stable ventricular arrhythmias, The American Journal of Cardiology, vol.53, issue.5, pp.59-65, 1984.
DOI : 10.1016/0002-9149(84)90504-6

J. Tamargo, A. Capucci, and P. Mabo, Safety of Flecainide, Drug Safety, vol.91, issue.6A, pp.273-289, 2012.
DOI : 10.2165/11599950-000000000-00000

URL : https://hal.archives-ouvertes.fr/hal-00905782

E. Aliot, A. Capucci, and H. Crijns, Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation, Europace, vol.13, issue.2, pp.161-173, 2011.
DOI : 10.1093/europace/euq382

G. Conard and R. Ober, Metabolism of flecainide, The American Journal of Cardiology, vol.53, issue.5, pp.41-51, 1984.
DOI : 10.1016/0002-9149(84)90501-0

G. Conard, G. Cronheim, and H. Klempt, Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients, Arzneimittelforschung, vol.32, pp.155-159, 1982.

H. Duff, D. Roden, and R. Maffucci, Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide, The American Journal of Cardiology, vol.48, issue.6, 1981.
DOI : 10.1016/0002-9149(81)90331-3

M. Hodges, J. Haugland, and G. Granrud, Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent, Circulation, vol.65, issue.5, pp.879-885, 1982.
DOI : 10.1161/01.CIR.65.5.879

J. Anderson, J. Stewart, and B. Perry, Oral Flecainide Acetate for the Treatment of Ventricular Arrhythmias, New England Journal of Medicine, vol.305, issue.9, pp.473-477, 1981.
DOI : 10.1056/NEJM198108273050901

D. Kiblboeck, M. Braeuer-mocker, P. Siostrzonek, and J. Reisinger, A misguided Bpill in the pocket^ approach with flecainide leading to cardiac arrest, BMJ Case Rep, pp.10-1136, 2012.

J. Anderson, J. Lutz, and S. Allison, Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia, Journal of the American College of Cardiology, vol.2, issue.1, pp.105-114, 1983.
DOI : 10.1016/S0735-1097(83)80382-9

J. Morganroth and L. Horowitz, Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram, The American Journal of Cardiology, vol.53, issue.5, pp.89-94, 1984.
DOI : 10.1016/0002-9149(84)90509-5

B. Holmes and R. Heel, Flecainide A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy, Drugs, vol.29, issue.1, pp.1-33, 1985.
DOI : 10.2165/00003495-198529010-00001

S. Ting, D. Lee, D. Maclean, and N. Sheerin, Paranoid Psychosis and Myoclonus: Flecainide Toxicity in Renal Failure, Cardiology, vol.111, issue.2, pp.83-86, 2008.
DOI : 10.1159/000119694

D. Salerno, G. Granrud, and P. Sharkey, Pharmacodynamics and side effects of flecainide acetate, Clinical Pharmacology and Therapeutics, vol.40, issue.1, pp.101-107, 1986.
DOI : 10.1038/clpt.1986.145

M. Homma, K. Kuga, and K. Doki, Assessment of serum flecainide trough levels in patients with tachyarrhythmia, Journal of Pharmacy and Pharmacology, vol.28, issue.1, pp.47-51, 2005.
DOI : 10.1211/0022357055128

S. Ranger and S. Nattel, Determinants and Mechanisms of Flecainide-Induced Promotion of Ventricular Tachycardia in Anesthetized Dogs, Circulation, vol.92, issue.5, pp.1300-1311, 1995.
DOI : 10.1161/01.CIR.92.5.1300

J. Coromilas, A. Saltman, and B. Waldecker, Electrophysiological Effects of Flecainide on Anisotropic Conduction and Reentry in Infarcted Canine Hearts, Circulation, vol.91, issue.8, pp.2245-2263, 1995.
DOI : 10.1161/01.CIR.91.8.2245

M. Restivo, H. Yin, and E. Caref, Reentrant Arrhythmias in the Subacute Infarction Period : The Proarrhythmic Effect of Flecainide Acetate on Functional Reentrant Circuits, Circulation, vol.91, issue.4, pp.1236-1246, 1995.
DOI : 10.1161/01.CIR.91.4.1236

D. Echt, P. Liebson, and L. Mitchell, Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo, New England Journal of Medicine, vol.324, issue.12, pp.781-788, 1991.
DOI : 10.1056/NEJM199103213241201

H. Kennedy, M. Brooks, and A. Barker, Beta-blocker therapy in the cardiac arrhythmia suppression trial, The American Journal of Cardiology, vol.74, issue.7, pp.674-680, 1994.
DOI : 10.1016/0002-9149(94)90308-5

K. Muhiddin, P. Turner, and A. Blackett, Effect of flecainide on cardiac output, Clinical Pharmacology and Therapeutics, vol.37, issue.3, pp.260-263, 1985.
DOI : 10.1038/clpt.1985.37

A. Nathan, K. Hellestrand, and R. Bexton, The Proarrhythmic Effects of Flecainide, Drugs, vol.29, issue.Supplement 4, pp.45-53, 1985.
DOI : 10.2165/00003495-198500294-00010

N. Estes, H. Garan, and J. Ruskin, Electrophysiologic properties of flecainide acetate, The American Journal of Cardiology, vol.53, issue.5, pp.26-29, 1984.
DOI : 10.1016/0002-9149(84)90498-3

J. Anderson, J. Stewart, and B. Crevey, A proposal for the clinical use of flecainide, The American Journal of Cardiology, vol.53, issue.5, pp.112-119, 1984.
DOI : 10.1016/0002-9149(84)90514-9

K. Hellestrand, R. Bexton, and A. Nathan, Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man., Heart, vol.48, issue.2, pp.140-148, 1982.
DOI : 10.1136/hrt.48.2.140

G. Boriani, I. Diemberger, and M. Biffi, Pharmacological Cardioversion of Atrial Fibrillation, Drugs, vol.24, issue.24, pp.2741-2762, 2004.
DOI : 10.2165/00003495-200464240-00003

R. Falk, Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter, Annals of Internal Medicine, vol.117, issue.2, pp.141-150, 1992.
DOI : 10.7326/0003-4819-117-2-141

K. Hellestrand, A. Nathan, R. Bexton, and A. Camm, Response of an Abnormal Sinus Node to Intravenous Flecainide Acetate, Pacing and Clinical Electrophysiology, vol.6, issue.3, pp.436-439, 1984.
DOI : 10.1016/0002-9149(82)90423-4

P. Serruys, G. Vanhaleweyk, and M. Van-den-brand, The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease., British Journal of Clinical Pharmacology, vol.1, issue.1, pp.51-59, 1983.
DOI : 10.1111/j.1365-2125.1983.tb02143.x

D. Paola, A. Horowitz, L. Morganroth, and J. , Influence of left ventricular dysfunction on flecainide therapy, Journal of the American College of Cardiology, vol.9, issue.1, pp.163-168, 1987.
DOI : 10.1016/S0735-1097(87)80096-7

M. Josephson, S. Kaul, and J. Hopkins, Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease, American Heart Journal, vol.109, issue.1, pp.41-45, 1985.
DOI : 10.1016/0002-8703(85)90413-2

A. Cohen, V. Daru, and G. Covelli, Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction, American Heart Journal, vol.110, issue.6, pp.1193-1196, 1985.
DOI : 10.1016/0002-8703(85)90011-0

V. Legrand, P. Materne, and M. Vandormael, Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy, European Heart Journal, vol.6, issue.8, pp.664-671, 1985.
DOI : 10.1093/oxfordjournals.eurheartj.a061918

A. Harmer, J. Valentin, and C. Pollard, channel and drug-induced prolongation of the QRS complex, British Journal of Pharmacology, vol.52, issue.1, pp.260-273, 2011.
DOI : 10.1111/j.1476-5381.2011.01415.x

A. Williams, R. Mcquinn, and J. Walls, Pharmacokinetics of flecainide acetate in patients with severe renal impairment, Clinical Pharmacology and Therapeutics, vol.43, issue.4, pp.449-455, 1988.
DOI : 10.1038/clpt.1988.57

J. Braun, J. Kollert, and J. Becker, Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function, European Journal of Clinical Pharmacology, vol.6, issue.6, pp.711-714, 1987.
DOI : 10.1007/BF00541300

S. Forland, E. Burgess, and A. Blair, Oral Flecainide Pharmacokinetics in Patients with Impaired Renal Function, The Journal of Clinical Pharmacology, vol.12, issue.suppl B, pp.259-267, 1988.
DOI : 10.1002/j.1552-4604.1988.tb03142.x

S. Forland, R. Cutler, and R. Mcquinn, Flecainide Pharmacokinetics After Multiple Dosing in Patients with Impaired Renal Function, The Journal of Clinical Pharmacology, vol.73, issue.Suppl 4, pp.727-735, 1988.
DOI : 10.1002/j.1552-4604.1988.tb03207.x

S. Hohnloser and M. Zabel, Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias, The American Journal of Cardiology, vol.70, issue.5, pp.3-9, 1992.
DOI : 10.1016/0002-9149(92)91071-B

H. Blix, K. Viktil, T. Moger, and A. Reikvam, Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients, Pharmacy Practice (Internet), vol.8, issue.1, pp.50-55, 2010.
DOI : 10.4321/S1886-36552010000100006

L. Tennezé, E. Tarral, N. Ducloux, and C. Funck-brentano, Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: Comparison with the standard form and influence of the CYP2D6 polymorphism*, Clinical Pharmacology & Therapeutics, vol.72, issue.2, pp.112-122125946, 2002.
DOI : 10.1067/mcp.2002.125946

K. Doki, M. Homma, and K. Kuga, CYP2D6 genotype affects age-related decline in flecainide clearance, Pharmacogenetics and Genomics, vol.22, issue.11, pp.777-783, 2012.
DOI : 10.1097/FPC.0b013e3283588fe5

K. Doki, M. Homma, and K. Kuga, Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia, European Journal of Clinical Pharmacology, vol.106, issue.11, pp.919-926, 2006.
DOI : 10.1007/s00228-006-0188-x

K. Doki, M. Homma, and K. Kuga, genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism, British Journal of Clinical Pharmacology, vol.46, issue.1, pp.89-96, 2009.
DOI : 10.1111/j.1365-2125.2009.03435.x

C. Funck-brentano, L. Becquemont, and H. Kroemer, Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone, Clinical Pharmacology and Therapeutics, vol.55, issue.3, pp.256-269, 1994.
DOI : 10.1038/clpt.1994.26

G. Mikus, A. Gross, and J. Beckmann, The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide, Clinical Pharmacology and Therapeutics, vol.45, issue.5, pp.562-567, 1989.
DOI : 10.1038/clpt.1989.73

K. Lim, J. Cho, and I. Jang, Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects, Br J Clin Pharmacol, vol.66, pp.660-666, 2008.

L. Bertilsson, Y. Lou, and Y. Du, Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin, Clinical Pharmacology and Therapeutics, vol.51, issue.4, pp.388-397, 1992.
DOI : 10.1038/clpt.1992.38

C. Palmiere, L. Mdel, M. Sabatasso, and S. , Usefulness of postmortem biochemistry in forensic pathology: Illustrative case reports, Legal Medicine, vol.14, issue.1, pp.27-35, 2012.
DOI : 10.1016/j.legalmed.2011.10.004

Y. Tsao and J. Gugger, Delirium in a Patient with Toxic Flecainide Plasma Concentrations: The Role of a Pharmacokinetic Drug Interaction with Paroxetine, Annals of Pharmacotherapy, vol.41, issue.8, pp.1366-1369, 2009.
DOI : 10.1345/aph.1M067

E. Pritchett and W. Wilkinson, Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias, The American Journal of Cardiology, vol.67, issue.11, 1991.
DOI : 10.1016/0002-9149(91)90170-P

M. Wehling, Meta-analysis of Flecainide Safety in Patients with Supraventricular Arrhythmias, Arzneimittelforschung, vol.52, issue.07, pp.507-51410, 2002.
DOI : 10.1055/s-0031-1299923

E. Aliot, D. Roy, L. Capucci, and A. , Safety of a controlled-release flecainide acetate formulation in the??prevention of paroxysmal atrial fibrillation in outpatients, Annales de Cardiologie et d'Ang??iologie, vol.52, issue.1, pp.34-40, 2003.
DOI : 10.1016/S0003-3928(02)00183-X

S. Andersen, M. Hansen, and G. Gislason, Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card, Cell Electrophysiol Eur Soc Cardiol, vol.11, pp.886-891, 2009.

N. Freemantle, C. Lafuente-lafuente, and S. Mitchell, Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation . Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card, Cell Electrophysiol Eur Soc Cardiol, vol.13, pp.329-345, 2011.

D. 'alessandro, L. Rieder, M. Gloor, and J. , Life-Threatening Flecainide Intoxication in a Young Child Secondary to Medication Error, Annals of Pharmacotherapy, vol.100, issue.9, pp.1522-1527, 2009.
DOI : 10.1345/aph.1L549

A. Khavandi and P. Walker, Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics, Emergency Medicine Journal, vol.24, issue.5, p.44362, 2006.
DOI : 10.1136/emj.2006.044362

R. Taylor, M. Gandhi, and G. Lloyd, Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide, BMJ, vol.340, issue.mar10 3, p.4684, 2010.
DOI : 10.1136/bmj.b4684

P. Friedman and W. Stevenson, Proarrhythmia, The American Journal of Cardiology, vol.82, issue.7, pp.50-58, 1998.
DOI : 10.1016/S0002-9149(98)00586-4

G. Naccarelli, D. Wolbrette, and J. Luck, Proarrhythmia, Medical Clinics of North America, vol.85, issue.2, pp.503-526, 2001.
DOI : 10.1016/S0025-7125(05)70324-2

H. Almroth, T. Andersson, and E. Fengsrud, The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events, Journal of Internal Medicine, vol.108, issue.3, pp.281-290, 2011.
DOI : 10.1111/j.1365-2796.2011.02395.x

J. Anderson, E. Gilbert, and B. Alpert, Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group, Circulation, vol.80, issue.6, pp.1557-1570, 1989.
DOI : 10.1161/01.CIR.80.6.1557

H. Crijns, V. Gelder, I. , V. Gilst, and W. , Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter, The American Journal of Cardiology, vol.68, issue.4, pp.335-341, 1991.
DOI : 10.1016/0002-9149(91)90828-9

M. Gulizia, S. Mangiameli, and S. Orazi, A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial, American Heart Journal, vol.155, issue.1, pp.100-107, 2008.
DOI : 10.1016/j.ahj.2007.08.033

A. Pietersen and H. Hellemann, Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter, The American Journal of Cardiology, vol.67, issue.8, pp.713-717, 1991.
DOI : 10.1016/0002-9149(91)90527-R

I. Sihm, F. Hansen, and J. Rasmussen, Flecainide acetate in atrial flutter and fibrillation, European Heart Journal, vol.11, issue.2, pp.145-148, 1990.
DOI : 10.1093/oxfordjournals.eurheartj.a059670

L. Van-wijk, P. Den-heijer, and H. Crijns, Flecainide Versus Quinidine in the Prevention of Paroxysms of Atrial Fibrillation, Journal of Cardiovascular Pharmacology, vol.13, issue.1, pp.32-36, 1989.
DOI : 10.1097/00005344-198901000-00005

E. Aliot and I. Denjoy, Comparison of the safety and efficacy of flecamide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter, The American Journal of Cardiology, vol.77, issue.3, pp.66-71, 1996.
DOI : 10.1016/S0002-9149(97)89120-5

A. Carunchio, M. Fera, and A. Mazza, A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation, G Ital Cardiol, vol.25, pp.51-68, 1995.

M. Chimienti, M. Cullen, and G. Casadei, Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias, European Heart Journal, vol.16, issue.12, pp.1943-1951, 1995.
DOI : 10.1093/oxfordjournals.eurheartj.a060852

G. Naccarelli, P. Dorian, S. Hohnloser, and P. Coumel, Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter, The American Journal of Cardiology, vol.77, issue.3, pp.53-59, 1996.
DOI : 10.1016/S0002-9149(97)89118-7

I. Van-gelder, H. Crijns, V. Gilst, and W. , Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter, The American Journal of Cardiology, vol.64, issue.19, 1989.
DOI : 10.1016/0002-9149(89)90574-2

C. Lafuente-lafuente, M. Longas-tejero, J. Bergmann, and J. Belmin, Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation, Cochrane Database Syst Rev, vol.5, 2012.

C. Lafuente-lafuente, S. Mouly, M. Longas-tejero, and J. Bergmann, Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation, Cochrane Database Syst Rev, 2007.

R. Mcnamara, L. Tamariz, J. Segal, and E. Bass, Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography, Annals of Internal Medicine, vol.139, issue.12, pp.1018-1033, 2003.
DOI : 10.7326/0003-4819-139-12-200312160-00012

J. Balthasar, Bioequivalence and bioequivalency testing, Am J Pharm Educ, vol.63, pp.194-198, 1999.

R. Beyth and R. Shorr, Principles of drug therapy in older patients: rational drug prescribing, Clinics in Geriatric Medicine, vol.18, issue.3, pp.577-592, 2002.
DOI : 10.1016/S0749-0690(02)00017-4

R. Kasmer, A. Nara, and J. Green, Comparable steadystate bioavailability between two preparations of conventionalrelease procainamide hydrochloride, Drug Intell Clin Pharm, vol.21, pp.183-186, 1987.

D. Hilleman, A. Patterson, and S. Mohiuddin, Comparative bioequivalence and efficacy of two sustained-release, 1988.